Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Intraflagellar transport protein 88 homolog (**IFT88**) is a core component of the **intraflagellar transport-B (IFT-B) complex**, required for the formation and maintenance of cilia and flagella in eukaryotic cells[1][3]. As a member of the tetratricopeptide repeat (TPR) family, IFT88 mediates assembly of macromolecular complexes that shuttle structural and signaling proteins along ciliary and flagellar axonemes, primarily by interacting with other IFT-B proteins such as IFT52 and IFT70, and with motor proteins like kinesin-2 for anterograde movement[3][4][6]. IFT88 is indispensable for ciliogenesis; its absence results in failure to form functional cilia and flagella, underlying a range of **ciliopathies** such as polycystic kidney disease and congenital anosmia[1][2][5]. Beyond ciliary roles, IFT88 regulates cell cycle progression, ensuring proper spindle orientation and planar cell polarity in dividing cells[1][2]. Mutations or silencing of IFT88 disrupt essential signaling pathways within the cilium, leading to defects in organ development, neural function, and tissue homeostasis, particularly affecting kidney, cartilage, and neural tissue[1][5][6]. Animal models and cell studies demonstrate that loss of IFT88 impairs cilia length and function, confirming its status as a critical structural and regulatory protein but not a classical druggable target[4]. IFT88 serves as a molecular marker in experimental studies for ciliary diseases and is commonly used to investigate the mechanism of ciliogenesis and centrosome-cilia cross-talk in development and disease[1][3][4][6].
Not applicable; there are no drugs currently known to act on IFT88
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Intraflagellar transport protein 88 homolog (IFT88).